Sanders Capital Holding in Meritage Homes (MTH) Decreased by $6.34 Million; Venbio Select Advisor Has Decreased Position in Aerie Pharmaceuticals (AERI) as Stock Declined

December 7, 2017 - By Adrian Erickson

Venbio Select Advisor Llc decreased its stake in Aerie Pharmaceuticals Inc (AERI) by 45.68% based on its latest 2017Q2 regulatory filing with the SEC. Venbio Select Advisor Llc sold 194,158 shares as the company’s stock declined 8.47% while stock markets rallied. The institutional investor held 230,842 shares of the health care company at the end of 2017Q2, valued at $12.13M, down from 425,000 at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Aerie Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.11B market cap company. The stock decreased 2.55% or $1.5 during the last trading session, reaching $57.4. About 335,271 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since December 7, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Sanders Capital Llc decreased its stake in Meritage Homes Corp (MTH) by 4.24% based on its latest 2017Q2 regulatory filing with the SEC. Sanders Capital Llc sold 140,940 shares as the company’s stock rose 18.89% with the market. The institutional investor held 3.18M shares of the homebuilding company at the end of 2017Q2, valued at $145.54M, down from 3.32M at the end of the previous reported quarter. Sanders Capital Llc who had been investing in Meritage Homes Corp for a number of months, seems to be less bullish one the $2.06 billion market cap company. The stock decreased 1.26% or $0.65 during the last trading session, reaching $51.1. About 378,652 shares traded or 23.73% up from the average. Meritage Homes Corporation (NYSE:MTH) has risen 18.92% since December 7, 2016 and is uptrending. It has outperformed by 2.22% the S&P500.




Investors sentiment decreased to 1.18 in 2017 Q2. Its down 0.50, from 1.68 in 2017Q1. It fall, as 20 investors sold MTH shares while 42 reduced holdings. 29 funds opened positions while 44 raised stakes. 39.12 million shares or 0.65% more from 38.87 million shares in 2017Q1 were reported. 93,512 were accumulated by New York State Teachers Retirement Sys. Impact Advsr Ltd Liability accumulated 29,459 shares or 0.57% of the stock. Nj State Employees Deferred Compensation Plan holds 0.12% in Meritage Homes Corporation (NYSE:MTH) or 15,000 shares. Cim Mangement Incorporated invested 0.11% in Meritage Homes Corporation (NYSE:MTH). Qs Ltd Liability Company reported 0% in Meritage Homes Corporation (NYSE:MTH). Millennium Mgmt Limited Company accumulated 969,102 shares. Principal Fincl reported 0.01% stake. 848,480 are owned by Hexavest. Envestnet Asset stated it has 1,522 shares. Balyasny Asset Management Llc reported 0.07% of its portfolio in Meritage Homes Corporation (NYSE:MTH). Indexiq Advsr Limited Liability Company has invested 0.03% in Meritage Homes Corporation (NYSE:MTH). Amer Intll Grp Inc holds 0% in Meritage Homes Corporation (NYSE:MTH) or 28,759 shares. The Minnesota-based Ameriprise Finance Inc has invested 0% in Meritage Homes Corporation (NYSE:MTH). Sei Invests owns 0% invested in Meritage Homes Corporation (NYSE:MTH) for 4,042 shares. Aperio Gp Limited Liability Corporation invested in 0.01% or 25,678 shares.

Sanders Capital Llc, which manages about $15.69 billion and $16.92 billion US Long portfolio, upped its stake in Bp Plc (NYSE:BP) by 745,414 shares to 3.92M shares, valued at $135.72 million in 2017Q2, according to the filing. It also increased its holding in Pepsico Inc (NYSE:PEP) by 1.63 million shares in the quarter, for a total of 3.86 million shares, and has risen its stake in Pfizer Inc (NYSE:PFE).

More notable recent Meritage Homes Corporation (NYSE:MTH) news were published by: Fool.com which released: “Meritage Homes Corp Builds Better Results on Strong Orders, New Communities” on May 01, 2017, also Globenewswire.com with their article: “Meritage Homes Second Quarter 2017 Earnings Release and Webcast Conference …” published on June 30, 2017, Globenewswire.com published: “Meritage Homes to Develop 183 Townhomes and Single-Family Homes in Coveted …” on November 01, 2017. More interesting news about Meritage Homes Corporation (NYSE:MTH) were released by: Globenewswire.com and their article: “Meritage Homes to Include Advanced Wireless Home Automation Package in New Homes” published on July 05, 2017 as well as Fool.com‘s news article titled: “Meritage Homes Corp. Finishes 2016 Strong, but a Few Things Bear Watching” with publication date: February 02, 2017.

Analysts await Meritage Homes Corporation (NYSE:MTH) to report earnings on February, 7. They expect $1.26 earnings per share, up 3.28% or $0.04 from last year’s $1.22 per share. MTH’s profit will be $50.82 million for 10.14 P/E if the $1.26 EPS becomes a reality. After $1.02 actual earnings per share reported by Meritage Homes Corporation for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Among 17 analysts covering Meritage (NYSE:MTH), 1 have Buy rating, 2 Sell and 14 Hold. Therefore 6% are positive. Meritage had 45 analyst reports since July 30, 2015 according to SRatingsIntel. On Thursday, April 7 the stock rating was upgraded by Barclays Capital to “Overweight”. The firm has “Equal-Weight” rating given on Tuesday, October 13 by Barclays Capital. Keefe Bruyette & Woods maintained Meritage Homes Corporation (NYSE:MTH) rating on Tuesday, August 1. Keefe Bruyette & Woods has “Hold” rating and $4500 target. FBR Capital maintained Meritage Homes Corporation (NYSE:MTH) on Monday, November 2 with “Mkt Perform” rating. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, October 19. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Wednesday, October 4 report. The rating was downgraded by Zelman on Monday, July 11 to “Hold”. The stock of Meritage Homes Corporation (NYSE:MTH) has “Mkt Perform” rating given on Friday, July 29 by FBR Capital. The rating was maintained by JP Morgan on Monday, November 2 with “Neutral”. The firm earned “Sell” rating on Friday, August 14 by Zacks.

Among 14 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 42 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, September 20 by H.C. Wainwright. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cowen & Co on Wednesday, August 2. The firm has “Buy” rating by H.C. Wainwright given on Thursday, July 20. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus on Thursday, July 27. RBC Capital Markets maintained the shares of AERI in report on Thursday, September 15 with “Outperform” rating. The rating was maintained by Cantor Fitzgerald on Thursday, July 20 with “Buy”. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Wednesday, October 11 by Cantor Fitzgerald. The rating was maintained by Cowen & Co with “Buy” on Thursday, November 9. The firm has “Buy” rating by TH Capital given on Friday, February 17. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Friday, August 7 with “Buy” rating.

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Businesswire.com which released: “Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional …” on December 04, 2017, also Businesswire.com with their article: “Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of …” published on December 01, 2017, Seekingalpha.com published: “Biotech drug pricing should not get substantially worse next year – Mizuho” on December 06, 2017. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Zacks.com and their article: “Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals …” published on December 07, 2017 as well as Seekingalpha.com‘s news article titled: “Aerie Pharmaceuticals’ (AERI) CEO Vicente Anido on Q3 2017 Results – Earnings …” with publication date: November 09, 2017.

Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.21, from 0.96 in 2017Q1. It is positive, as 21 investors sold AERI shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported. Alliancebernstein Lp accumulated 377,384 shares. Legal And General Gru Public Limited Co invested in 0% or 7,534 shares. Ubs Oconnor Ltd Liability Corporation holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 30,181 shares. Partner Investment Mgmt Ltd Partnership holds 2.29% or 32,496 shares in its portfolio. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 3,711 shares. Partner Fund Mgmt LP stated it has 2.47% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Hbk LP holds 40,800 shares or 0.02% of its portfolio. Moreover, Geode Cap Management Lc has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Principal Fincl Gp Inc has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Iguana Management Ltd Liability Corp owns 95,000 shares. Fincl Consulate reported 0.57% stake. Envestnet Asset Mngmt owns 414 shares for 0% of their portfolio. Gsa Cap Prtn Limited Liability Partnership reported 4,906 shares or 0.02% of all its holdings. Hanseatic Mngmt Services holds 0% or 16 shares. Dafna Capital Mngmt Ltd Co holds 106,770 shares.

Venbio Select Advisor Llc, which manages about $380.08 million and $791.97M US Long portfolio, upped its stake in Teligent Inc by 339,288 shares to 4.13M shares, valued at $37.80 million in 2017Q2, according to the filing. It also increased its holding in Array Biopharma Inc (NASDAQ:ARRY) by 3.31M shares in the quarter, for a total of 4.18 million shares, and has risen its stake in Clovis Oncology Inc (NASDAQ:CLVS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.